ウイルス性呼吸器感染症治療市場のサイズ分析、2031年まで

世界のウイルス性呼吸器感染症治療市場

Market Size in USD Billion

CAGR : 8.50 %

予測期間	2024 –2031
市場規模（基準年）	USD 57,365.34 Million
Market Size (Forecast Year)	USD 108,207.05 Million
CAGR	8.50 %
Major Markets Players	Pfizer GSK Gilead Sciences F. Hoffmann La Roche Johnson & Johnson

>世界のウイルス性呼吸器感染症治療市場、治療タイプ別（抗ウイルス薬、ワクチン、モノクローナル抗体、非ステロイド性抗炎症薬（NSAIDs）、その他）、タイプ別（OTCおよび処方箋ベース）、投与経路別（経口、経鼻、注射）、疾患タイプ別（COVID、インフルエンザ（FLU）、RSウイルス（RSV）、パラインフルエンザ、アデノウイルス、ライノウイルス（風邪）、エンテロウイルス、抗炎症薬、その他）、感染タイプ別（上気道感染症および下気道感染症）、人口別（小児、成人、高齢者）、性別別（男性および女性）、エンドユーザー別（病院、在宅ケア施設、診療所、研究機関および学術センター、外来手術センター）、流通チャネル別（直接入札、小売販売、その他） - 業界動向および2020年までの予測2031年。

ウイルス性呼吸器感染症治療市場の分析と規模

ウイルス性呼吸器感染症の蔓延の増加が市場の成長を牽引しています。しかし、厳格な規制承認プロセスが市場の成長を抑制しています。一方で、共同研究活動やパートナーシップの増加により、市場の成長の機会が生まれることが期待されています。

データブリッジマーケットリサーチは、世界のウイルス性呼吸器感染症治療市場は、2023年の573億6,534万米ドルから2031年には1,082億705万米ドルに達し、2024年から2031年の予測期間に8.5%のCAGRで成長すると分析しています。

レポートメトリック	詳細
予測期間	2024年から2031年
基準年	2023
歴史的な年	2022 (カスタマイズ可能 2016-2021)
定量単位	収益（百万米ドル）
対象セグメント	治療タイプ（抗ウイルス薬、ワクチン、モノクローナル抗体、非ステロイド性抗炎症薬（NSAIDs）、その他）、タイプ（OTCおよび処方箋ベース）、投与経路（経口、経鼻、注射）、疾患タイプ（新型コロナウイルス、インフルエンザ（FLU）、RSウイルス（RSV）、パラインフルエンザ、アデノウイルス、ライノウイルス（風邪）、エンテロウイルス、抗炎症薬、その他）、感染タイプ（上気道感染症および下気道感染症）、対象者（小児、成人、高齢者）、性別（男性および女性）、エンドユーザー（病院、在宅ケア施設、診療所、研究機関および学術センター、外来手術センター）、流通チャネル（直接入札、小売販売、その他）
対象国	米国、カナダ、メキシコ、ドイツ、イタリア、英国、フランス、スイス、スペイン、ロシア、トルコ、ベルギー、オランダ、その他のヨーロッパ諸国、中国、インド、韓国、日本、タイ、オーストラリア、シンガポール、インドネシア、マレーシア、フィリピン、その他のアジア太平洋諸国、ブラジル、アルゼンチン、その他の南米諸国、サウジアラビア、UAE、南アフリカ、エジプト、イスラエル、その他の中東およびアフリカ諸国
対象となる市場プレーヤー	ファイザー社、GSK社、ギリアド・サイエンシズ社、F.ホフマン・ラ・ロシュ社、ジョンソン・エンド・ジョンソン社、シノバック・ファミリー、リリー社、アストラゼネカ社、リジェネロン・ファーマシューティカルズ社、バーラト・バイオテック社、スウェーデン・オーファン・バイオビトラム社、セラム・インスティテュート・オブ・インディア社、バイオロジカル・E・リミテッド社、セルトリオン・ヘルスケア社、インフラックス社など

市場の定義

ウイルス性呼吸器感染症の治療には、呼吸器系に影響を及ぼすウイルスによって引き起こされる病気と闘うことを目的とした幅広い医療処置が含まれます。風邪、インフルエンザ、RSウイルス（RSV）、アデノウイルス、そして最近ではCOVID-19の原因であるSARS-CoV-2などの新しいウイルスを含む多くの病気は、主に鼻、喉、副鼻腔、肺に影響を与えるこれらの病気によって引き起こされます。これらの病気の治療には通常、抗ウイルス薬、症状を軽減するための支持療法、特定の病気を防ぐための予防接種、さらに深刻な状況では酸素療法や人工呼吸器などの最先端技術による入院など、さまざまな戦略が使用されています。治療効果を高め、症状の強さを軽減し、これらの非常に伝染性の高い呼吸器感染症の伝染を阻止するための新しい抗ウイルス薬、ワクチン、治療法の開発は、医学の進歩によって常に促進されています。

世界のウイルス性呼吸器感染症治療市場の動向

このセクションでは、市場の推進要因、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。

ドライバー

ウイルス性呼吸器感染症の蔓延増加

インフルエンザ、RSウイルス（RSV）などの呼吸器感染症の発生率の上昇と、COVID-19パンデミックの世界的な影響により、効果的な治療オプションの需要が高まっています。世界人口の増加、都市化や海外旅行などの要因が相まって、呼吸器ウイルスの急速な蔓延に寄与し、治療介入を必要とする患者プールが大量に発生しています。

政府の取り組みとワクチン接種プログラム

世界中の政府は、ウイルス性呼吸器感染症が公衆衛生に及ぼす重大な影響を認識し、その蔓延を抑制するための戦略的取り組みを実施しています。最も効果的な対策の 1 つは、インフルエンザ、肺炎、COVID-19 などの主要なウイルス性呼吸器感染症の予防を目的としたワクチン接種プログラムの推進と広範な実施です。政府は、ワクチンの幅広いアクセスと手頃な価格を確保するために多大なリソースを投資しており、世界的なワクチン接種範囲の拡大に貢献しています。

機会

共同研究活動とパートナーシップの拡大

ウイルス性呼吸器疾患は複雑なため、製薬会社、学術機関、政府、医療機関のパートナーシップを組み合わせた学際的な戦略が必要です。リソース、情報、スキルを組み合わせた共同研究イニシアチブにより、ウイルス性呼吸器感染症の治療におけるイノベーションのスピードが加速します。コラボレーションにより、情報、科学的発見、技術革新の交換が促進され、ウイルス、その働き、および考えられる治療アプローチのより徹底した理解につながります。これらのパートナーシップは、より効果的な医薬品開発および発見手順への道を提供します。研究者は、さまざまな視点と専門知識を結集することで、単独で作業する場合と比較して、新しい治療ターゲットを見つけ、革新的な抗ウイルス薬を作成し、ワクチン技術をより迅速かつ効率的に開発できます。

抑制/挑戦

熟練した医療従事者への依存

ウイルス性呼吸器感染症の効果的な診断と治療には、医療従事者の高い専門知識と経験が求められることがよくあります。特に特定の地域では、熟練した人材が不足しているため、医療サービスの円滑な提供が妨げられ、市場の成長の可能性が制限されています。

ウイルス性呼吸器感染症の管理は、正確な診断、適切な治療法の選択、患者のケアなど、複雑なため、専門スキルを持つ人材が必要です。感染症専門医、呼吸器科医、呼吸療法士などの資格のある医療従事者の不足は、医療サービスをタイムリーかつ効率的に提供することを妨げています。熟練した人材への依存は、専門医療従事者が不足している地域ではボトルネックとなります。

最近の動向

2023年8月、リジェネロン・ファーマシューティカルズ社とバイオメディカル先端研究開発局（BARDA）は、SARS-CoV-2感染予防のための新たなCOVID-19モノクローナル抗体療法の臨床開発、臨床製造、規制認可プロセスのサポートに関する契約を締結した。
2023年7月、SINOVACとPT Biofarmaは、インドネシアの在宅ワクチン接種市場と世界市場にサービスを提供するために両社の協力の取り組みが大きく前進したことを発表しました。

世界のウイルス性呼吸器感染症治療市場の範囲

世界のウイルス性呼吸器感染症治療市場は、治療の種類、タイプ、投与経路、疾患の種類、感染の種類、人口、性別、エンドユーザー、流通チャネルに基づいて、9 つの主要なセグメントに分類されています。

治療の種類

抗ウイルス薬
ワクチン
モノクローナル抗体
非ステロイド性抗炎症薬（NSAID）
その他

治療の種類に基づいて、市場は抗ウイルス薬、ワクチン、モノクローナル抗体、非ステロイド性抗炎症薬（NSAID）などに分類されます。

タイプ

店頭
処方箋に基づく

タイプに基づいて、市場はOTCと処方箋ベースに分類されます。

投与経路

オーラル
鼻腔
注射可能

投与経路に基づいて、市場は経口、経鼻、注射に分類されます。

病気の種類

COVID
インフルエンザ
呼吸器合胞体ウイルス（RSV）
パラインフルエンザ
アデノウイルス
ライノウイルス（風邪）
エンテロウイルス
その他

病気の種類に基づいて、市場は、COVID-19、インフルエンザ、RSウイルス（RSV）、パラインフルエンザ、アデノウイルス、ライノウイルス（風邪）、エンテロウイルスなどに分類されます。

感染タイプ

上気道感染症
下気道感染症

感染タイプに基づいて、市場は上気道感染症と下気道感染症に分類されます。

人口

小児科
大人
老年病

人口に基づいて、市場は小児、成人、高齢者に分類されます。

性別

男
女性

性別に基づいて、市場は男性と女性に分割されます。

エンドユーザー

病院
ホームケア設定
クリニック
研究機関および学術センター
外来手術センター

エンドユーザーに基づいて、市場は病院、在宅ケア施設、診療所、研究機関および学術センター、外来手術センターに分類されます。

流通チャネル

直接入札
小売販売
その他

流通チャネルに基づいて、市場は直接入札、小売販売、その他に分類されます。

世界のウイルス性呼吸器感染症治療市場の地域分析/洞察

この市場レポートで取り上げられている国は、米国、カナダ、メキシコ、ドイツ、イタリア、英国、フランス、スイス、スペイン、ロシア、トルコ、ベルギー、オランダ、その他のヨーロッパ諸国、中国、インド、韓国、日本、タイ、オーストラリア、シンガポール、インドネシア、マレーシア、フィリピン、その他のアジア太平洋諸国、ブラジル、アルゼンチン、その他の南米諸国、サウジアラビア、UAE、南アフリカ、エジプト、イスラエル、その他の中東およびアフリカ諸国です。

北米は、技術の進歩の高まりによる大規模な投資により、市場を支配すると予想されています。米国は、高度な医療施設、最先端の研究機関、確立された規制枠組みを特徴とする洗練された医療システムを有しているため、北米地域で支配的になると予想されています。ドイツは、優れた医療インフラ、大手製薬会社の集中、厳格な規制基準、戦略的な地理的位置、公衆衛生に対する積極的な姿勢により、ヨーロッパ地域で支配的になると予想されています。中国は、イノベーションに重点を置いた製薬部門が急速に拡大しているため、アジア太平洋地域で支配的になると予想されています。国内外の製薬会社の存在は、新しい抗ウイルス薬と治療薬の開発を促進するダイナミックなエコシステムに貢献しています。

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリューチェーン分析、技術動向、ポーターの 5 つの力の分析、ケーススタディなどのデータポイントは、各国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、グローバルブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、国内関税の影響、貿易ルートも考慮されます。

競争環境と世界のウイルス性呼吸器感染症治療市場シェア分析

世界のウイルス性呼吸器感染症治療市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の長所と短所、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータポイントは、市場に対する会社の重点にのみ関連しています。

世界のウイルス性呼吸器感染症治療市場で活動している主要な市場プレーヤーには、ファイザー社、GSK社、ギリアド・サイエンシズ社、F・ホフマン・ラ・ロシュ社、ジョンソン・エンド・ジョンソン社、シノバック・ファミリー、リリー社、アストラゼネカ社、リジェネロン・ファーマシューティカルズ社、バーラト・バイオテック社、スウェディッシュ・オーファン・バイオビトラム社（出版）、セラム・インスティテュート・オブ・インディア社、バイオロジカル・E・リミテッド社、セルトリオン・ヘルスケア社、インフラRx NV社などがあります。

SKU-70316

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

画像をクリックすると拡大します

インタラクティブなデータ分析ダッシュボード
成長の可能性が高い機会のための企業分析ダッシュボード
カスタマイズとクエリのためのリサーチアナリストアクセス
インタラクティブなダッシュボードによる競合分析
最新ニュース、更新情報、トレンド分析
包括的な競合追跡のためのベンチマーク分析のパワーを活用

デモのリクエスト

表のリスト

TABLE 1 BRAND REVENUE ANALYSIS FOR VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET

TABLE 2 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 3 GLOBAL NON-STEROIDAL ANTI- INFLAMMATORY DTUGS (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 4 GLOBAL NON-STEROIDAL ANTI- INFLAMMATORY DRUGS(NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 5 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 6 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 7 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 8 GLOBAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 9 GLOBAL VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 10 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 11 GLOBAL WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 12 GLOBAL COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 13 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT, 2022-2031 (USD MILLION)

TABLE 14 GLOBAL INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 15 GLOBAL MONOCLONAL ANTIIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 16 GLOBAL MONOCLONAL ANTIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 17 GLOBAL MONOCLONAL ANTIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 18 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 19 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 20 GLOBAL PRESCRIPTION BASED IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 21 GLOBAL OTC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 22 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 23 GLOBAL NASAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 24 GLOBAL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 25 GLOBAL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 26 GLOBAL INJECTABLE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 27 GLOBAL INJECTABLE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 28 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 29 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 30 GLOBAL RHINOVIRUS (COMMON COLD) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 31 GLOBAL RESPIRATORY SYNCYTIAL VIRUS (RSV) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 32 GLOBAL INFLUENZA (FLU) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 33 GLOBAL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 34 GLOBAL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 35 GLOBAL ADENOVIRUSES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 36 GLOBAL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 37 GLOBAL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 38 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 39 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 40 GLOBAL LOWER RESPIRATORY INFECTIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 41 GLOBAL UPPER RESPIRATORY INFECTIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 42 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 43 GLOBAL GERIATRIC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 44 GLOBAL PEDIATRIC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 45 GLOBAL ADULTS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 46 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 47 GLOBAL MALE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 48 GLOBAL FEMALE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 49 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 50 GLOBAL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 51 GLOBAL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 52 GLOBAL AMBULATORY SURGICAL CENTERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 53 GLOBAL CLINICS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 54 GLOBAL HOME CARE SETTINGS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 55 GLOBAL RESEARCH INSTITUTES AND ACADEMIC CENTERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 56 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 57 GLOBAL DIRECT TENDER IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 58 GLOBAL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 59 GLOBAL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 60 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 61 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 62 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 63 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 64 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 65 NORTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 66 NORTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 67 NORTH AMERICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 68 NORTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 69 NORTH AMERICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 70 NORTH AMERICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 71 NORTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 72 NORTH AMERICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 73 NORTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 74 NORTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 75 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 76 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 77 NORTH AMERICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 78 NORTH AMERICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 79 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 80 NORTH AMERICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 81 NORTH AMERICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 82 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 83 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 84 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 85 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 86 NORTH AMERICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 87 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 88 NORTH AMERICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 89 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 90 U.S. NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 91 U.S. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 92 U.S. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 93 U.S. VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 94 U.S. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 95 U.S. WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 96 U.S. COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 97 U.S. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 98 U.S. INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 99 U.S. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 100 U.S. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 101 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 102 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 103 U.S. ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 104 U.S. INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 105 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 106 U.S. PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 107 U.S. ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 108 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 109 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 110 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 111 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 112 U.S. HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 113 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 114 U.S. RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 115 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 116 CANADA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 117 CANADA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 118 CANADA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 119 CANADA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 120 CANADA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 121 CANADA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 122 CANADA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 123 CANADA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 124 CANADA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 125 CANADA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 126 CANADA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 127 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 128 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 129 CANADA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 130 CANADA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 131 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 132 CANADA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 133 CANADA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 134 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 135 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 136 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 137 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 138 CANADA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 139 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 140 CANADA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 141 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 142 MEXICO NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 143 MEXICO ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 144 MEXICO ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 145 MEXICO VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 146 MEXICO COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 147 MEXICO WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 148 MEXICO COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 149 MEXICO COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 150 MEXICO INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 151 MEXICO MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 152 MEXICO MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 153 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 154 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 155 MEXICO ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 156 MEXICO INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 157 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 158 MEXICO PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 159 MEXICO ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 160 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 161 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 162 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 163 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 164 MEXICO HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 165 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 166 MEXICO RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 167 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 168 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 169 EUROPE NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 170 EUROPE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 171 EUROPE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 172 EUROPE VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 173 EUROPE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 174 EUROPE WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 175 EUROPE COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 176 EUROPE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 177 EUROPE INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 178 EUROPE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 179 EUROPE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 180 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 181 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 182 EUROPE ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 183 EUROPE INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 184 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 185 EUROPE PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 186 EUROPE ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 187 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 188 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 189 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 190 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 191 EUROPE HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 192 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 193 EUROPE RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 194 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 195 GERMANY NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 196 GERMANY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 197 GERMANY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 198 GERMANY VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 199 GERMANY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 200 GERMANY WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 201 GERMANY COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 202 GERMANY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 203 GERMANY INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 204 GERMANY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 205 GERMANY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 206 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 207 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 208 GERMANY ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 209 GERMANY INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 210 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 211 GERMANY PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 212 GERMANY ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 213 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 214 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 215 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 216 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 217 GERMANY HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 218 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 219 GERMANY RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 220 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 221 FRANCE NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 222 FRANCE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 223 FRANCE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 224 FRANCE VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 225 FRANCE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 226 FRANCE WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 227 FRANCE COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 228 FRANCE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 229 FRANCE INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 230 FRANCE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 231 FRANCE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 232 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 233 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 234 FRANCE ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 235 FRANCE INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 236 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 237 FRANCE PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 238 FRANCE ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 239 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 240 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 241 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 242 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 243 FRANCE HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 244 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 245 FRANCE RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 246 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 247 U.K. NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 248 U.K. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 249 U.K. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 250 U.K. VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 251 U.K. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 252 U.K. WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 253 U.K. COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 254 U.K. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 255 U.K. INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 256 U.K. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 257 U.K. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 258 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 259 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 260 U.K. ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 261 U.K. INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 262 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 263 U.K. PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 264 U.K. ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 265 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 266 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 267 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 268 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 269 U.K. HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 270 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 271 U.K. RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 272 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 273 ITALY NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 274 ITALY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 275 ITALY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 276 ITALY VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 277 ITALY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 278 ITALY WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 279 ITALY COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 280 ITALY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 281 ITALY INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 282 ITALY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 283 ITALY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 284 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 285 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 286 ITALY ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 287 ITALY INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 288 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 289 ITALY PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 290 ITALY ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 291 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 292 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 293 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 294 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 295 ITALY HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 296 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 297 ITALY RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 298 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 299 RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 300 RUSSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 301 RUSSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 302 RUSSIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 303 RUSSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 304 RUSSIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 305 RUSSIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 306 RUSSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 307 RUSSIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 308 RUSSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 309 RUSSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 310 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 311 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 312 RUSSIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 313 RUSSIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 314 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 315 RUSSIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 316 RUSSIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 317 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 318 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 319 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 320 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 321 RUSSIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 322 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 323 RUSSIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 324 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 325 SPAIN NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 326 SPAIN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 327 SPAIN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 328 SPAIN VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 329 SPAIN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 330 SPAIN WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 331 SPAIN COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 332 SPAIN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 333 SPAIN INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 334 SPAIN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 335 SPAIN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 336 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 337 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 338 SPAIN ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 339 SPAIN INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 340 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 341 SPAIN PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 342 SPAIN ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 343 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 344 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 345 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 346 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 347 SPAIN HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 348 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 349 SPAIN RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 350 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 351 TURKEY NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 352 TURKEY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 353 TURKEY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 354 TURKEY VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 355 TURKEY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 356 TURKEY WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 357 TURKEY COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 358 TURKEY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 359 TURKEY INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 360 TURKEY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 361 TURKEY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 362 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 363 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 364 TURKEY ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 365 TURKEY INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 366 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 367 TURKEY PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 368 TURKEY ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 369 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 370 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 371 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 372 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 373 TURKEY HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 374 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 375 TURKEY RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 376 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 377 NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 378 NETHERLANDS ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 379 NETHERLANDS ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 380 NETHERLANDS VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 381 NETHERLANDS COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 382 NETHERLANDS WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 383 NETHERLANDS COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 384 NETHERLANDS COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 385 NETHERLANDS INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 386 NETHERLANDS MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 387 NETHERLANDS MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 388 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 389 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 390 NETHERLANDS ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 391 NETHERLANDS INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 392 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 393 NETHERLANDS PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 394 NETHERLANDS ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 395 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 396 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 397 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 398 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 399 NETHERLANDS HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 400 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 401 NETHERLANDS RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 402 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 403 SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 404 SWITZERLAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 405 SWITZERLAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 406 SWITZERLAND VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 407 SWITZERLAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 408 SWITZERLAND WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 409 SWITZERLAND COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 410 SWITZERLAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 411 SWITZERLAND INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 412 SWITZERLAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 413 SWITZERLAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 414 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 415 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 416 SWITZERLAND ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 417 SWITZERLAND INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 418 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 419 SWITZERLAND PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 420 SWITZERLAND ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 421 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 422 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 423 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 424 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 425 SWITZERLAND HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 426 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 427 SWITZERLAND RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 428 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 429 BELGIUM NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 430 BELGIUM ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 431 BELGIUM ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 432 BELGIUM VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 433 BELGIUM COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 434 BELGIUM WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 435 BELGIUM COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 436 BELGIUM COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 437 BELGIUM INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 438 BELGIUM MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 439 BELGIUM MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 440 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 441 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 442 BELGIUM ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 443 BELGIUM INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 444 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 445 BELGIUM PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 446 BELGIUM ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 447 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 448 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 449 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 450 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 451 BELGIUM HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 452 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 453 BELGIUM RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 454 REST OF EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 455 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 456 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 457 ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 458 ASIA-PACIFIC ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 459 ASIA-PACIFIC ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 460 ASIA-PACIFIC VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 461 ASIA-PACIFIC COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 462 ASIA-PACIFIC WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 463 ASIA-PACIFIC COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 464 ASIA-PACIFIC COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 465 ASIA-PACIFIC INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 466 ASIA-PACIFIC MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 467 ASIA-PACIFIC MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 468 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 469 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 470 ASIA-PACIFIC ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 471 ASIA-PACIFIC INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 472 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 473 ASIA-PACIFIC PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 474 ASIA-PACIFIC ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 475 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 476 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 477 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 478 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 479 ASIA-PACIFIC HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 480 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 481 ASIA-PACIFIC RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 482 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 483 CHINA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 484 CHINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 485 CHINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 486 CHINA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 487 CHINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 488 CHINA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 489 CHINA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 490 CHINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 491 CHINA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 492 CHINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 493 CHINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 494 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 495 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 496 CHINA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 497 CHINA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 498 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 499 CHINA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 500 CHINA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 501 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 502 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 503 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 504 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 505 CHINA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 506 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 507 CHINA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 508 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 509 JAPAN NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 510 JAPAN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 511 JAPAN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 512 JAPAN VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 513 JAPAN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 514 JAPAN WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 515 JAPAN COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 516 JAPAN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 517 JAPAN INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 518 JAPAN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 519 JAPAN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 520 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 521 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 522 JAPAN ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 523 JAPAN INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 524 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 525 JAPAN PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 526 JAPAN ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 527 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 528 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 529 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 530 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 531 JAPAN HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 532 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 533 JAPAN RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 534 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 535 INDIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 536 INDIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 537 INDIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 538 INDIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 539 INDIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 540 INDIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 541 INDIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 542 INDIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 543 INDIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 544 INDIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 545 INDIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 546 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 547 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 548 INDIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 549 INDIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 550 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 551 INDIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 552 INDIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 553 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 554 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 555 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 556 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 557 INDIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 558 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 559 INDIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 560 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 561 SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 562 SOUTH KOREA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 563 SOUTH KOREA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 564 SOUTH KOREA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 565 SOUTH KOREA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 566 SOUTH KOREA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 567 SOUTH KOREA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 568 SOUTH KOREA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 569 SOUTH KOREA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 570 SOUTH KOREA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 571 SOUTH KOREA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 572 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 573 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 574 SOUTH KOREA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 575 SOUTH KOREA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 576 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 577 SOUTH KOREA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 578 SOUTH KOREA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 579 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 580 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 581 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 582 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 583 SOUTH KOREA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 584 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 585 SOUTH KOREA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 586 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 587 AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 588 AUSTRALIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 589 AUSTRALIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 590 AUSTRALIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 591 AUSTRALIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 592 AUSTRALIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 593 AUSTRALIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 594 AUSTRALIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 595 AUSTRALIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 596 AUSTRALIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 597 AUSTRALIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 598 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 599 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 600 AUSTRALIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 601 AUSTRALIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 602 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 603 AUSTRALIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 604 AUSTRALIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 605 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 606 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 607 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 608 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 609 AUSTRALIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 610 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 611 AUSTRALIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 612 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 613 SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 614 SINGAPORE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 615 SINGAPORE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 616 SINGAPORE VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 617 SINGAPORE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 618 SINGAPORE WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 619 SINGAPORE COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 620 SINGAPORE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 621 SINGAPORE INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 622 SINGAPORE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 623 SINGAPORE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 624 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 625 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 626 SINGAPORE ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 627 SINGAPORE INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 628 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 629 SINGAPORE PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 630 SINGAPORE ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 631 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 632 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 633 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 634 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 635 SINGAPORE HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 636 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 637 SINGAPORE RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 638 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 639 THAILAND NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 640 THAILAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 641 THAILAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 642 THAILAND VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 643 THAILAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 644 THAILAND WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 645 THAILAND COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 646 THAILAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 647 THAILAND INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 648 THAILAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 649 THAILAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 650 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 651 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 652 THAILAND ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 653 THAILAND INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 654 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 655 THAILAND PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 656 THAILAND ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 657 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 658 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 659 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 660 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 661 THAILAND HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 662 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 663 THAILAND RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 664 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 665 MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 666 MALAYSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 667 MALAYSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 668 MALAYSIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 669 MALAYSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 670 MALAYSIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 671 MALAYSIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 672 MALAYSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 673 MALAYSIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 674 MALAYSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 675 MALAYSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 676 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 677 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 678 MALAYSIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 679 MALAYSIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 680 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 681 MALAYSIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 682 MALAYSIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 683 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 684 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 685 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 686 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 687 MALAYSIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 688 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 689 MALAYSIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 690 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 691 INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 692 INDONESIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 693 INDONESIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 694 INDONESIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 695 INDONESIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 696 INDONESIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 697 INDONESIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 698 INDONESIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 699 INDONESIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 700 INDONESIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 701 INDONESIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 702 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 703 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 704 INDONESIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 705 INDONESIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 706 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 707 INDONESIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 708 INDONESIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 709 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 710 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 711 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 712 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 713 INDONESIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 714 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 715 INDONESIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 716 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 717 PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 718 PHILIPPINES ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 719 PHILIPPINES ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 720 PHILIPPINES VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 721 PHILIPPINES COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 722 PHILIPPINES WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 723 PHILIPPINES COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 724 PHILIPPINES COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 725 PHILIPPINES INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 726 PHILIPPINES MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 727 PHILIPPINES MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 728 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 729 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 730 PHILIPPINES ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 731 PHILIPPINES INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 732 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 733 PHILIPPINES PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 734 PHILIPPINES ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 735 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 736 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 737 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 738 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 739 PHILIPPINES HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 740 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 741 PHILIPPINES RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 742 REST OF ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 743 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 744 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 745 SOUTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 746 SOUTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 747 SOUTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 748 SOUTH AMERICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 749 SOUTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 750 SOUTH AMERICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 751 SOUTH AMERICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 752 SOUTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 753 SOUTH AMERICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 754 SOUTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 755 SOUTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 756 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 757 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 758 SOUTH AMERICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 759 SOUTH AMERICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 760 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 761 SOUTH AMERICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 762 SOUTH AMERICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 763 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 764 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 765 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 766 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 767 SOUTH AMERICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 768 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 769 SOUTH AMERICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 770 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 771 BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 772 BRAZIL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 773 BRAZIL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 774 BRAZIL VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 775 BRAZIL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 776 BRAZIL WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 777 BRAZIL COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 778 BRAZIL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 779 BRAZIL INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 780 BRAZIL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 781 BRAZIL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 782 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 783 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 784 BRAZIL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 785 BRAZIL INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 786 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 787 BRAZIL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 788 BRAZIL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 789 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 790 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 791 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 792 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 793 BRAZIL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 794 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 795 BRAZIL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 796 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 797 ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 798 ARGENTINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 799 ARGENTINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 800 ARGENTINA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 801 ARGENTINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 802 ARGENTINA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 803 ARGENTINA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 804 ARGENTINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 805 ARGENTINA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 806 ARGENTINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 807 ARGENTINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 808 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 809 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 810 ARGENTINA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 811 ARGENTINA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 812 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 813 ARGENTINA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 814 ARGENTINA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 815 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 816 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 817 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 818 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 819 ARGENTINA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 820 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 821 ARGENTINA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 822 REST OF SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 823 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 824 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 825 MIDDLE EAST AND AFRICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 826 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 827 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 828 MIDDLE EAST AND AFRICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 829 MIDDLE EAST AND AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 830 MIDDLE EAST AND AFRICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 831 MIDDLE EAST AND AFRICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 832 MIDDLE EAST AND AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 833 MIDDLE EAST AND AFRICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 834 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 835 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 836 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 837 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 838 MIDDLE EAST AND AFRICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 839 MIDDLE EAST AND AFRICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 840 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 841 MIDDLE EAST AND AFRICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 842 MIDDLE EAST AND AFRICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 843 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 844 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 845 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 846 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 847 MIDDLE EAST AND AFRICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 848 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 849 MIDDLE EAST AND AFRICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 850 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 851 SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 852 SOUTH AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 853 SOUTH AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 854 SOUTH AFRICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 855 SOUTH AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 856 SOUTH AFRICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 857 SOUTH AFRICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 858 SOUTH AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 859 SOUTH AFRICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 860 SOUTH AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 861 SOUTH AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 862 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 863 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 864 SOUTH AFRICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 865 SOUTH AFRICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 866 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 867 SOUTH AFRICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 868 SOUTH AFRICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 869 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 870 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 871 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 872 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 873 SOUTH AFRICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 874 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 875 SOUTH AFRICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 876 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 877 SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 878 SAUDI ARABIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 879 SAUDI ARABIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 880 SAUDI ARABIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 881 SAUDI ARABIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 882 SAUDI ARABIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 883 SAUDI ARABIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 884 SAUDI ARABIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 885 SAUDI ARABIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 886 SAUDI ARABIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 887 SAUDI ARABIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 888 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 889 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 890 SAUDI ARABIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 891 SAUDI ARABIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 892 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 893 SAUDI ARABIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 894 SAUDI ARABIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 895 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 896 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 897 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 898 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 899 SAUDI ARABIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 900 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 901 SAUDI ARABIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 902 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 903 U.A.E. NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 904 U.A.E. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 905 U.A.E. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 906 U.A.E. VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 907 U.A.E. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 908 U.A.E. WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 909 U.A.E. COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 910 U.A.E. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 911 U.A.E. INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 912 U.A.E. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 913 U.A.E. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 914 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 915 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 916 U.A.E. ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 917 U.A.E. INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 918 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 919 U.A.E. PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 920 U.A.E. ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 921 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 922 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 923 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 924 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 925 U.A.E. HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 926 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 927 U.A.E. RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 928 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 929 EGYPT NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 930 EGYPT ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 931 EGYPT ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 932 EGYPT VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 933 EGYPT COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 934 EGYPT WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 935 EGYPT COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 936 EGYPT COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 937 EGYPT INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 938 EGYPT MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 939 EGYPT MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 940 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 941 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 942 EGYPT ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 943 EGYPT INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 944 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 945 EGYPT PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 946 EGYPT ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 947 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 948 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 949 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 950 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 951 EGYPT HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 952 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 953 EGYPT RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 954 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 955 ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 956 ISRAEL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 957 ISRAEL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 958 ISRAEL VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 959 ISRAEL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 960 ISRAEL WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 961 ISRAEL COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 962 ISRAEL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 963 ISRAEL INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 964 ISRAEL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 965 ISRAEL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 966 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 967 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 968 ISRAEL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 969 ISRAEL INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 970 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 971 ISRAEL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 972 ISRAEL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 973 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 974 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 975 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 976 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 977 ISRAEL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 978 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 979 ISRAEL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 980 REST OF MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

図表一覧

FIGURE 1 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SEGMENTATION

FIGURE 10 NORTH AMERICA REGION IS EXPECTED TO DOMINATE THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET AND GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 11 THE INCREASING PREVALENCE OF VIRAL RESPIRATORY DISEASES IS DRIVING THE GROWTH OF THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 12 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET IN 2024 AND 2031

FIGURE 13 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET

FIGURE 15 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, 2023

FIGURE 16 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, 2024-2031 (USD MILLION)

FIGURE 17 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2024-2031)

FIGURE 18 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 19 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, 2023

FIGURE 20 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)

FIGURE 21 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 22 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 24 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)

FIGURE 25 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 26 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 27 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, 2023

FIGURE 28 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, 2024-2031 (USD MILLION)

FIGURE 29 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, CAGR (2024-2031)

FIGURE 30 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 31 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, 2023

FIGURE 32 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, 2024-2031 (USD MILLION)

FIGURE 33 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, CAGR (2024-2031)

FIGURE 34 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, LIFELINE CURVE

FIGURE 35 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, 2023

FIGURE 36 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, 2024-2031 (USD MILLION)

FIGURE 37 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, CAGR (2024-2031)

FIGURE 38 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, LIFELINE CURVE

FIGURE 39 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, 2023

FIGURE 40 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)

FIGURE 41 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, CAGR (2024-2031)

FIGURE 42 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 43 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, 2023

FIGURE 44 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)

FIGURE 45 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, CAGR (2024-2031)

FIGURE 46 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 48 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 49 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 50 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SNAPSHOT (2023)

FIGURE 52 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 53 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 54 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 55 AISA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)

詳細情報を見る

調査方法

データ収集と基準年分析は、大規模なサンプルサイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データマイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データモデルには、ベンダーポジショニンググリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニンググリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダーシェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータスタイルでいくつでも追加できます。当社のアナリストチームは、粗い生の Excel ファイルピボットテーブル (ファクトブック) でデータを提供したり、レポートで利用可能なデータセットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

What are the primary segments covered in the Global Viral Respiratory Infections Treatment Market report?

The market is segmented based on , By Treatment Type (Antiviral Medications, Vaccine, Monoclonal Antibodies, Non-steroidal Anti-inflammatory Drugs (NSAIDs), and Others), Type (OTC and Prescription Based), Route of Administration (Oral, Nasal, and Injectable), Disease Type (Covid, Influenza (FLU), Respiratory Syncytial Virus (RSV), Parainfluenza, Adenoviruses, Rhinovirus (Common Cold), Enterovirus, Anti-inflammatory, and Others), Infection Type (Upper Respiratory Infections and Lower Respiratory Infections), Population (Pediatric, Adults, and Geriatric), Gender (Male and Female), End User (Hospitals, Home Care Settings, Clinics, Research Institutes and Academic Centers, and Ambulatory Surgical Centers), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2031. .

What is the current market size of the Global Viral Respiratory Infections Treatment Market?

The Global Viral Respiratory Infections Treatment Market size was valued at USD 57365.34 USD Million in 2023.

What is the expected growth rate of the Global Viral Respiratory Infections Treatment Market?

The Global Viral Respiratory Infections Treatment Market is projected to grow at a CAGR of 8.5% during the forecast period of 2024 to 2031.

Who are the key players in the Global Viral Respiratory Infections Treatment Market?

The major players operating in the market include Pfizer, GSK, Gilead Sciences, F. Hoffmann La Roche, Johnson & Johnson, SINOVAC FAMILY, Lilly, AstraZeneca, Regeneron Pharmaceuticals, Bharat Biotech, Swedish Orphan Biovitrum AB, Serum Institute of India Pvt. , Biological E Limited, Celltrion Healthcare Co., InflaRx N.V..

Which countries are analyzed in the Global Viral Respiratory Infections Treatment Market report?

The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel and Rest of Middle East and Africa.

世界のウイルス性呼吸器感染症治療市場 – 2031 年までの業界動向と予測

世界のウイルス性呼吸器感染症治療市場 – 2031 年までの業界動向と予測

世界のウイルス性呼吸器感染症治療市場

CAGR : 8.50 %

ウイルス性呼吸器感染症治療市場の分析と規模

世界のウイルス性呼吸器感染症治療市場の動向

世界のウイルス性呼吸器感染症治療市場の範囲

世界のウイルス性呼吸器感染症治療市場の地域分析/洞察

競争環境と世界のウイルス性呼吸器感染症治療市場シェア分析

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

目次

表のリスト

図表一覧

調査方法

カスタマイズ可能

Frequently Asked Questions

レポート

市場洞察

サポート

ソリューション

世界のウイルス性呼吸器感染症治療市場 – 2031 年までの業界動向と予測

世界のウイルス性呼吸器感染症治療市場 – 2031 年までの業界動向と予測

世界のウイルス性呼吸器感染症治療市場

CAGR : 8.50 %

ウイルス性呼吸器感染症治療市場の分析と規模

世界のウイルス性呼吸器感染症治療市場の動向

世界のウイルス性呼吸器感染症治療市場の範囲

世界のウイルス性呼吸器感染症治療市場の地域分析/洞察

競争環境と世界のウイルス性呼吸器感染症治療市場シェア分析

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

目次

表のリスト

図表一覧

調査方法

カスタマイズ可能

Frequently Asked Questions

関連ページを閲覧する